Intelligence · Clinical pipeline
Oncology R&D Pipeline
Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Quick answer
Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Top sponsors
- First People's Hospital 474 programs
- Chinese Academy of 400 programs
- United Therapeutics Europe 219 programs
- George Institute for 172 programs
- Takeda 163 programs
- HOFFMANN-LA ROCHE 144 programs
- AstraZeneca 143 programs
- MSD Merck Sharp 131 programs
- Regeneron UK 128 programs
- Anaxis Pharma 125 programs
- Telethon Foundation 113 programs
- Novartis India 110 programs
Pipeline programs
-
Health Promotion and Education
BRIGHT MINDS BIOSCIENCES INC.
Cigarette Smoking-Related Carcinoma
1 trial -
Hema-NeoTIL01
The First People's Hospital of Lianyungang
Leukemia, Myeloid, Acute
1 trial -
Hemay020
Tianjin Hemay Pharmaceutical Co., Ltd
Neoplasms，Non-Small Cell Lung Cancer
1 trial -
HepaVac-201
Fondazione Telethon ETS
Hepatocellular carcinoma
1 trial -
I-131-CLR1404
Cellectar Biosciences
Cancer
1 trial -
I-131-CLR1404
Cellectar Biosciences
Solid Tumors
1 trial -
I124-NM404
Cellectar Biosciences
Non Small Cell Lung Cancer
1 trial -
I3Y-MC-JPCE
Eli Lilly Co.
Lung Cancer or Breast Cancer
1 trial -
I3Y-MC-JPEI
Eli Lilly Co.
Prostatic Neoplasms
1 trial -
IBR733 Cell Injection
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia
1 trial -
IC 2018-06
The George Institute
Patients with recurrent and/or metastatic solid cancer.
1 trial -
IC 2022-10
The George Institute
Patients with pretreated, metastatic or locally advanced cancer for the dose escalation part and dose expansion cohorts in patients with advanced triple-negative breast cancers and advanced cancers with ATM mutation.
1 trial -
ICG-Cisplatin Nanoprobe (NIR-II NanoM)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Liver Cancer, Adult
1 trial -
ICO-2023-16
CERO THERAPEUTICS HOLDINGS, INC.
cell lung carcinoma
1 trial -
ICO-2023-25 OPTIMISE
CERO THERAPEUTICS HOLDINGS, INC.
metastatic prostate cancer
1 trial -
ID-LV305
Lxo Ireland Designated Activity Company
Melanoma - Currently Enrolling
1 trial -
IDC-G305
Lxo Ireland Designated Activity Company
Melanoma
1 trial -
IDE-161
IDEAYA Biosciences
Advanced or Metastatic Solid Tumors
1 trial -
IDE034
IDEAYA Biosciences
Esophageal Squamous Cell Carcinoma
1 trial -
IDE397
IDEAYA Biosciences
Solid Tumor
1 trial -
IDE397-001
IDEAYA Biosciences
Advanced Solid Tumors
1 trial -
IDE892
IDEAYA Biosciences
NSCLC Adenocarcinoma
1 trial -
IFx-Hu2.0
TuHURA Biosciences, Inc./NV
Cutaneous Melanoma, Stage III
1 trial -
IFx-Hu2.0
TuHURA Biosciences, Inc./NV
Merkel Cell Carcinoma
1 trial -
IFx-Hu2.0
TuHURA Biosciences, Inc./NV
Cutaneous Squamous Cell Carcinoma
1 trial -
IIT2025079
Xiyuan Hospital of China Academy of Chinese Medical Sciences
AML - Acute Myeloid Leukemia
1 trial -
IL-2
Alaunos Therapeutics
Lymphoma
1 trial -
IL-22BP mRNA vaccine injection
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Refractory Malignant Solid Tumors
1 trial -
IMATI-10-25
Lacuna Pharma Pty Ltd
Acute Lymphoblastic Leukemia (Ph+ ALL), (Ph+) Chronic Myeloid Leukemia
1 trial -
IMP3-saRNA (YMN-136) Vaccine
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non-Small Cell Lung Cancer
1 trial -
INBRX-105 - PDL1x41BB antibody
Inhibrx Biosciences
Metastatic Solid Tumors
1 trial -
INBRX-109
Inhibrx Biosciences
Ewing Sarcoma
1 trial -
INC280 single agent
Novartis Pharmaceuticals
Non-Small Cell Lung Cancer
1 trial -
INCA 33989-101
Incyte
Myeloproliferative Neoplasms
1 trial -
INCA33890
Incyte
Solid Tumors
1 trial -
INCB 123667-101
Incyte
Advanced or metastatic solid tumors
1 trial -
INCB 161734-101
Incyte
Advanced or metastatic solid tumors
1 trial -
INCB 99280-205
Incyte
Solid tumor
1 trial -
INCB099280
Incyte
Advanced Solid Tumor
1 trial -
INCB160058-101
Incyte
Myeloproliferative Neoplasms
1 trial -
INO-1400
INOVIO PHARMACEUTICALS, INC.
Breast Cancer
1 trial -
INO-3106, INO-9012
INOVIO PHARMACEUTICALS, INC.
Aerodigestive Precancerous Lesions and Malignancies
1 trial -
INSIGHT
The George Institute
Histologically confirmed locally advanced or metastatic solid tumor (Strata A, B, D): Specification for Stratum C: Only patients with NSCLC adenocarcinomas, (squamous or adenosquamous not permitted) who are scheduled to receive platin + pembrolizumab + pemetrexed standard treatment (only for Stratum C) Specification for Stratum E: Including only metastatic or irresectable locally advanced urothelial carcinomas (only for Stratum E)
1 trial -
INTERACT stomach
Disc Medicine
Stomach Cancer with metastasis in the peritoneum
1 trial -
INXN-1001
Alaunos Therapeutics
Melanoma
1 trial -
IO-108
BEONE MEDICINES AUS PTY LTD
Solid Tumor, Adult
1 trial -
IO-108
BEONE MEDICINES AUS PTY LTD
Advanced Solid Tumor
1 trial -
IO-202
BEONE MEDICINES AUS PTY LTD
Solid Tumor, Adult
1 trial
Frequently asked questions
How many oncology pipeline programs are tracked?
5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.
Where does pipeline data come from?
ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.